Filed Pursuant to Rule 424(b)(5)
File Nos. 333-269608
AMENDMENT NO. 1 TO
PROSPECTUS SUPPLEMENT
(To Prospectus dated February 9, 2023)
14,072,615 Shares of Common Stock
Warrants to Purchase up to 14,072,615 Shares of Common Stock
and
the Shares of
Common Stock underlying the Warrants
This Amendment
No. 1 to Prospectus Supplement (the “Amendment”) modifies, supersedes and supplements information contained in, and should be read in conjunction with, that certain prospectus supplement previously filed with the Securities and
Exchange Commission on February 16, 2023 (the “Prospectus Supplement”) and an accompanying prospectus forming part of the “shelf” registration statement on Form S-3 (Registration No. 333-269608), including a base prospectus, previously filed with the SEC on February 7, 2023 and declared effective by the SEC on February 9, 2023. The Prospectus Supplement relates to the offer
and sale of 14,072,615 shares of our common stock, par value $0.0001 per share (the “common stock”), and warrants to purchase up to 14,072,615 shares of our common stock (and the shares of common stock issuable from time to
time upon exercise of those warrants). Each share of common stock sold in the offering was accompanied by a warrant to purchase one share of our common stock at an exercise price of $4.2636 per share. Each share of common stock and the
accompanying warrant was sold at a combined offering price of $3.5530. Subject to certain ownership limitations, the warrants were immediately exercisable, and the warrants had an expiration date two years after the initial issuance date. The
shares of common stock and the warrants were issued separately. We refer to the shares of common stock and the accompanying warrants, including the underlying shares of common stock, issued in that offering, collectively, as the
“securities.”
This Amendment is not complete without and may not be delivered or used except in connection with, the Prospectus
Supplement and all other amendments thereto.
The information contained in this Amendment modifies and supersedes, in part, the
information in the Prospectus Supplement. Any information that is modified or superseded in the Prospectus Supplement shall not be deemed to constitute a part of the Prospectus Supplement, except as modified or superseded by this Amendment.
We may amend or supplement the Prospectus Supplement from time to time by filing amendments or supplements as required. You should read the
entire Prospectus Supplement and any amendments or supplements carefully before you make an investment decision.
Investing in
our securities involves significant risks. See “Risk Factors” beginning on page S-7 of the Prospectus Supplement and on page 5 of the accompanying base prospectus, as well as the information